



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 81652

**Title:** Current and novel modalities for management of chronic hepatitis B infection

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06474545

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Research Assistant

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-11-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-16 07:58

**Reviewer performed review:** 2023-01-03 07:42

**Review time:** 17 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No
------------	---------------------------------------

### **SPECIFIC COMMENTS TO AUTHORS**

The manuscript, submitted for publication by Salama et al., is a review article focused on treatment of chronic hepatitis B infection, as well as emphasized new treatment modalities. They have underlined new specific molecular treatments promising a new era for CHB. This paper can be used to guide the use of these new treatments and guide physicians in terms of further studies. However, there are some issues and questions that should be addressed in the study.

- 1- There are reviews quite a lot on this topic on this topic (doi: 10.3389/fmicb.2022.975584 , doi: 10.3390/ph14050417). In fact, recently published reviews contain almost the same information. The authors should clarify the aim of this study and difference from other reviews
- 2- I recommend using more up-to-date data when giving epidemiologic data about prevalence and incidence for hepatitis B infection.
- 3- Headlines and subheadings related to treatment modalities and new developments can be better organized.
- 4- Please explain the particles associated with the HBV and their functions at the cellular level in more detail. All the molecular-based information should be collected under the introduction part all together or the subheadings related to the specific treatment.
- 5- Authors could make more table and figure to explain better your points. I suggest improving the presentation and quality of figure and table. (Please summarize CHB treatments in tables for easy reading experience).
- 6- The discussion section is scarce, and they do not sufficiently highlight the originality and the significant contributions of the study. Therefore, they need to be rearranged.
- 7- As an output of the study, what is the most recommending/promising therapy for CHB between all new treatments. Please define which treatment modalities is better for which patient group in detailed (please categorize specific treatments according to their side effects or benefits for specific patient groups, e.g. adults/children.)



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

8-The English language used throughout the manuscript needs some improvements in terms of style and grammar ( for example Please rephrase this headline “Intoduction” and please spellcheck all text carefully) 9- Specify abbreviations where they are first mentioned in the text carefully.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 81652

**Title:** Current and novel modalities for management of chronic hepatitis B infection

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05311389

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor, Research Fellow

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-11-19

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2023-01-13 14:36

**Reviewer performed review:** 2023-01-25 15:57

**Review time:** 12 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

This is a review that explains the current novelty in chronic HBV infection treatment. It mainly highlights the preclinical basis and mechanism of HBV drugs that are under investigation. There are some typos and English mistakes that should be corrected. I have only one commentary: in “author contribution” you state that some authors are responsible for HAV, HCV, HDV and HEV writing, but these topics are not present in the review. I think it is a mistake.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 81652

**Title:** Current and novel modalities for management of chronic hepatitis B infection

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 01560784

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Chief Doctor, Chief Physician, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-11-19

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2023-01-18 02:54

**Reviewer performed review:** 2023-01-26 09:05

**Review time:** 8 Days and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

Hepatitis B virus infection is a major public health problem facing the world today. Chronic hepatitis B virus infection can cause chronic hepatitis, liver failure, cirrhosis and liver cancer. At present, there are two main types of drugs used in clinical treatment of chronic hepatitis B virus infection, including nucleos(t)ide analogues and IFN- $\alpha$  and Peg-IFN, but none of them can effectively remove the virus and cure chronic hepatitis B. It is a challenge for the medical community to completely eliminate hepatitis B virus infection. Chronic HBV infection is the result of the interaction between the virus and the host. The unique replication mode of HBV plays a key role in the establishment and maintenance of continuous infection in hepatocytes. This manuscript expounds the current research progress of curing hepatitis B virus infection from the aspects of virus and host factors. However, several reviews with the same content as this manuscript have been published.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 81652

**Title:** Current and novel modalities for management of chronic hepatitis B infection

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02444878

**Position:** Peer Reviewer

**Academic degree:** MD, MRCP, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-11-19

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2023-01-17 08:13

**Reviewer performed review:** 2023-01-27 09:50

**Review time:** 10 Days and 1 Hour

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

Title reflect the main subject/hypothesis of the manuscript. The manuscript interpret the findings adequately and appropriately, highlighting the key points concisely, clearly and logically. The findings and their applicability/relevance to the literature are stated in a clear and definite manner. The discussion is accurate and it discusses the paper’s scientific significance and/or relevance to clinical practice sufficiently.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 81652

**Title:** Current and novel modalities for management of chronic hepatitis B infection

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03262333

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-11-19

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2023-01-14 06:51

**Reviewer performed review:** 2023-01-27 20:07

**Review time:** 13 Days and 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



# Baishideng Publishing Group

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

There are several other reviews on the same topic in other journal . I do nit see any novelty in this review . There are no reference form the authors regarding the new treatments in this review , The organization of the article could have been more logic.